Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)
Close on Nov 17, 2026Market cap $10.88MP/E –Yield –
Bolt Biotherapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Bolt Biotherapeutics's revenue for the twelve months ending Sep 30, 2026 was $2.53M, down 51.3% year over year. For fiscal 2025 it was $7.70M, up 0.1% from the year before. The highest annual figure on record is $7.88M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.70M | +0.1% |
| FY2024 | Dec 31, 2024 | $7.69M | -2.4% |
| FY2023 | Dec 31, 2023 | $7.88M | +37.5% |
| FY2022 | Dec 31, 2022 | $5.73M | +354.7% |
| FY2021 | Dec 31, 2021 | $1.26M | +445.5% |
| FY2020 | Dec 31, 2020 | $231.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0 | -100.0% |
| Q2 FY2026 | Jun 30, 2026 | $5.00K | -99.7% |
| Q1 FY2026 | Mar 31, 2026 | $26.00K | -97.9% |
| Q4 FY2025 | Dec 31, 2025 | $2.50M | – |
| Q3 FY2025 | Sep 30, 2025 | $2.17M | +90.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.80M | +41.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.22M | -76.8% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.14M | -54.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.28M | -11.0% |
| Q1 FY2024 | Mar 31, 2024 | $5.27M | +188.8% |
| Q4 FY2023 | Dec 31, 2023 | $2.09M | +48.1% |
| Q3 FY2023 | Sep 30, 2023 | $2.53M | +19.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.43M | +2.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.83M | +124.6% |
| Q4 FY2022 | Dec 31, 2022 | $1.41M | +177.8% |
| Q3 FY2022 | Sep 30, 2022 | $2.11M | +180.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.39M | – |
| Q1 FY2022 | Mar 31, 2022 | $813.00K | – |
| Q4 FY2021 | Dec 31, 2021 | $508.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $752.00K | +1022.4% |
| Q2 FY2021 | Jun 30, 2021 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $67.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $164.00K | – |
See a number that looks wrong?